 Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
"Precursor B-Cell Lymphoblastic Leukemia-Lymphoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A leukemia/lymphoma found predominately in children and adolescents and characterized by a high number of lymphoblasts and solid tumor lesions. Frequent sites involve LYMPH NODES, skin, and bones. It most commonly presents as leukemia.
| Descriptor ID |
D015452
|
| MeSH Number(s) |
C04.557.337.428.600.600 C15.604.515.560.600.600 C20.683.515.528.600.600
|
| Concept/Terms |
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
- Precursor B Cell Lymphoblastic Leukemia Lymphoma
- Pre B-ALL
- Pre-B ALL
- Pre B ALL
- Precursor B-Cell Lymphoblastic Leukemia
- Precursor B Cell Lymphoblastic Leukemia
- Precursor B-Cell Lymphoblastic Lymphoma
- Precursor B Cell Lymphoblastic Lymphoma
- Leukemia, Pre-B-Cell
- Leukemia, Pre B Cell
- Leukemias, Pre-B-Cell
- Pre-B-Cell Leukemias
- Pre-B-Cell Leukemia
- Pre B Cell Leukemia
|
Below are MeSH descriptors whose meaning is more general than "Precursor B-Cell Lymphoblastic Leukemia-Lymphoma".
Below are MeSH descriptors whose meaning is more specific than "Precursor B-Cell Lymphoblastic Leukemia-Lymphoma".
This graph shows the total number of publications written about "Precursor B-Cell Lymphoblastic Leukemia-Lymphoma" by people in this website by year, and whether "Precursor B-Cell Lymphoblastic Leukemia-Lymphoma" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 1 | 1 | | 2006 | 1 | 0 | 1 | | 2008 | 1 | 0 | 1 | | 2009 | 2 | 0 | 2 | | 2012 | 1 | 0 | 1 | | 2013 | 5 | 0 | 5 | | 2015 | 5 | 1 | 6 | | 2016 | 3 | 0 | 3 | | 2017 | 4 | 1 | 5 | | 2018 | 5 | 0 | 5 | | 2019 | 5 | 2 | 7 | | 2020 | 4 | 0 | 4 | | 2021 | 5 | 0 | 5 | | 2022 | 1 | 1 | 2 | | 2023 | 9 | 0 | 9 | | 2024 | 6 | 1 | 7 | | 2025 | 6 | 0 | 6 | | 2026 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Precursor B-Cell Lymphoblastic Leukemia-Lymphoma" by people in Profiles.
-
Nishimura K, Isobe T, Shigehiro T, Nomura M, Zang W, Xiao M, Liao W, Koike Y, Nishimura A, Sato-Otsubo A, Yamazaki H, Ito H, Okada S, Matsumoto N, Saika W, Zhang Y, Aoyama Y, Hasegawa C, Yamasaki T, Kubota Y, Ohki K, Kiyokawa N, Nagae G, Yoshida K, Nannya Y, Ueno H, Fukuda S, Tatsuno K, Tsutsumi S, Shiozawa Y, Shiraishi Y, Chiba K, Tanaka H, Eguchi M, Arakawa Y, Koh K, Deguchi T, Tomizawa D, Miyamura T, Ishii E, Mizutani S, Miyano S, Aburatani H, Ogawa S, Takaori-Kondo A, Yokoyama A, Abdel-Wahab O, Ernst P, Takita J, Ikawa T, Takagi M, Inoue D. Comprehensive molecular and functional analysis of NUTM1-rearranged leukemia. Blood. 2026 Mar 26; 147(13):1395-1411.
-
Dreyzin A, Yates B, Shalabi H, Silbert SK, Wang HW, Yuan CM, Hoang CN, Culbert AA, Gava F, Nair MS, Giordani VM, Little L, Foley T, Nussenblatt V, Fry TJ, Stroncek DF, Highfill SL, Shah NN. Ten-year experience of CD22 CAR T cells for children and young adults with B-cell acute lymphoblastic leukemia. Blood Adv. 2026 Mar 10; 10(5):1700-1712.
-
Rangarajan HG, Satwani P, Herr MM, Chen M, Martens MJ, Wudhikarn K, John S, Fabrizio VA, Hsieh EM, Kelkar AH, Doherty E, Marks DI, Ringden O, Friend B, Kelly MS, Farhadfar N, Prestidge T, Hossain NM, Liu H, Hashmi S, Modi D, Winestone LE, El Boghdadly Z, Murthy HS, Perales MA, Chemaly RF, Dandoy CE, Hill JA, Huppler A, Riches M, Auletta JJ. Real-world outcomes of infections following tisagenlecleucel in patients with B-cell ALL: a CIBMTR analysis. Blood Adv. 2025 Nov 11; 9(21):5489-5500.
-
Deimundo Roura C, Amrolia P, Ansari M, Bader P, Balduzzi A, Buechner J, Hsieh EM, Myers RM, Ottaviano G, Peters C, Rouce RH, Shah NN, Verneris MR, Kalwak K, Pulsipher MA. Opportunities and Challenges With CAR T-cell Treatment of Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia: Review and Recommendations From the Westhafen Intercontinental Group. Transplant Cell Ther. 2026 Mar; 32(3):261-276.
-
Dreyzin A, Kramer AM, Yates B, Wang HW, Sahaf B, Yuan C, Klysz D, Tunuguntla R, Ehlinger Z, Reitberg S, Adebola S, Su A, Ebina-Shibuya R, Jia D, Achar S, Patil S, Martin K, Jeyakumar N, Davis KL, Fry T, Mackall CL, Taylor N, Altan-Bonnet G, Highfill S, Feldman S, Stroncek DF, Chien C, Schultz LM, Frank MJ, Muffly LS, Shalabi H, Ramakrishna S, Shah NN. Outcomes following CD22 CAR T-cells in B-ALL: a tale of two manufacturing strategies. Cytotherapy. 2026 Mar; 28(3):101990.
-
Iacobucci I, Zeng AGX, Gao Q, Garcia-Prat L, Baviskar P, Shah S, Murison A, Voisin V, Chan-Seng-Yue M, Cheng C, Qu C, Bailey C, Lear M, Witkowski MT, Zhou X, Zaldivar Peraza A, Gangwani K, Advani AS, Luger SM, Litzow MR, Rowe JM, Paietta EM, Stock W, Dick JE, Mullighan CG. Multipotent lineage potential in B cell acute lymphoblastic leukemia is associated with distinct cellular origins and clinical features. Nat Cancer. 2025 Jul; 6(7):1242-1262.
-
Hogan LE, Bhatla T, Xu X, Gore L, Raetz EA, Bhojwani D, Teachey DT, Hunger SP, Loh ML, Brown PA, Ji L. Severe toxicity and poor efficacy of reinduction chemotherapy are associated with overall poor outcomes in relapsed B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group AALL1331 trial. Haematologica. 2025 Dec 01; 110(12):2930-2941.
-
Wang'ondu RW, Ashcraft E, Chang TC, Roberts KG, Brady SW, Fan Y, Evans W, Relling MV, Crews KR, Yang J, Yang W, Pounds S, Wu G, Devidas M, Maloney K, Mattano L, Schore RJ, Angiolillo A, Larsen E, Salzer W, Burke MJ, Loh ML, Jeha S, Pui CH, Inaba H, Cheng C, Mullighan CG. Heterogeneity of IKZF1 genomic alterations and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia. Leukemia. 2025 Jul; 39(7):1595-1606.
-
Gupta S, Rau RE, Kairalla JA, Rabin KR, Wang C, Angiolillo AL, Alexander S, Carroll AJ, Conway S, Gore L, Kirsch I, Kubaney HR, Li AM, McNeer JL, Militano O, Miller TP, Moyer Y, O'Brien MM, Okada M, Reshmi SC, Shago M, Wagner E, Winick N, Wood BL, Haworth-Wright T, Zaman F, Zugmaier G, Zupanec S, Devidas M, Hunger SP, Teachey DT, Raetz EA, Loh ML. Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children. N Engl J Med. 2025 Feb 27; 392(9):875-891.
-
Jabbour EJ, Kantarjian HM, Goekbuget N, Shah BD, Chiaretti S, Park JH, Rijneveld AW, Gore L, Fleming S, Logan AC, Ribera JM, Menne TF, Mezzi K, Zaman F, Velasco K, Boissel N. Frontline Ph-negative B-cell precursor acute lymphoblastic leukemia treatment and the emerging role of blinatumomab. Blood Cancer J. 2024 11 19; 14(1):203.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|